Frontage Laboratories, Inc., a leading contract research organisation (CRO), is headquartered in the United States and operates extensively across North America, Europe, and Asia. Founded in 2001, Frontage has established itself as a key player in the pharmaceutical and biotechnology sectors, providing comprehensive services that span preclinical and clinical development. The company offers a unique blend of laboratory services, including bioanalytical testing, formulation development, and clinical trial management, distinguished by its commitment to quality and innovation. Frontage's strategic focus on integrating advanced technologies has positioned it as a trusted partner for clients seeking to navigate the complexities of drug development. With a strong market presence and a reputation for excellence, Frontage Laboratories continues to achieve significant milestones in advancing healthcare solutions.
How does Frontage Laboratories, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Frontage Laboratories, Inc.'s score of 38 is higher than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Frontage Laboratories, Inc., headquartered in the US, currently does not have specific carbon emissions data available for recent years. The company is a current subsidiary of Frontage Holdings Corporation, which may influence its climate commitments and emissions reporting. As part of its climate strategy, Frontage Laboratories inherits initiatives from its parent company, particularly from Frontage Holdings Corporation, which has been involved in various sustainability efforts. However, specific reduction targets or achievements have not been disclosed for Frontage Laboratories itself. Additionally, emissions data and climate commitments may also be influenced by the cascading initiatives from Hangzhou Tigermed Consulting Co., Ltd., which is at a cascade level of 3. This indicates that while Frontage Laboratories is part of a broader corporate family with potential climate initiatives, specific details regarding their own emissions and reduction targets remain unspecified. In summary, while Frontage Laboratories, Inc. is part of a corporate structure that may have climate commitments, there is currently no available data on their specific carbon emissions or reduction targets.
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 866,070 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 5,187,190 | 0,000,000 | 0,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - |
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Frontage Laboratories, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.